Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att bedöma säkerheten, tolerabiliteten och farmakokinetiken för ABSK-021 hos patienter med avancerad solid tumör

6 november 2026 uppdaterad av: Abbisko Therapeutics Co, Ltd

En öppen fas 1-studie av ABSK021 för att bedöma säkerhet, tolerabilitet och farmakokinetik hos patienter med avancerad solid tumör

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Studietyp

Interventionell

Inskrivning (Beräknad)

276

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • California
      • Beverly Hills, California, Förenta staterna, 90212
        • Aktiv, inte rekryterande
        • Precision NextGen Oncology
    • Colorado
      • Denver, Colorado, Förenta staterna, 80218-1238
        • Avslutad
        • SCRI at HealthOne
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Avslutad
        • The Winship Cancer Institute of Emory University
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Avslutad
        • MD Anderson Cancer Center
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Rekrytering
        • Beijing Jishuitan Hospital
        • Kontakt:
          • Xiaohui Niu, MD
        • Huvudutredare:
          • Xiaohui Niu, MD
    • Guangzhou
      • Guangdong, Guangzhou, Kina
        • Aktiv, inte rekryterande
        • The First Affiliated Hospital of Sun Yat-sen University
    • Hebei
      • Shijiazhuang, Hebei, Kina
        • Avslutad
        • Hebei Medical University Third Hospital
    • Henan
      • Zhengzhou, Henan, Kina
        • Avslutad
        • The First Affiliated Hospital of Zhengzhou Universtity
      • Zhengzhou, Henan, Kina
        • Aktiv, inte rekryterande
        • Henan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina
        • Aktiv, inte rekryterande
        • Nanjing Drum Tower Hospital
      • Nanjing, Jiangsu, Kina
        • Aktiv, inte rekryterande
        • Jiangsu Province Hospital
    • Liaoning
      • Shenyang, Liaoning, Kina
        • Avslutad
        • Liaoning Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Avslutad
        • Huashan Hospital of Fudan University
      • Shanghai, Shanghai Municipality, Kina
        • Avslutad
        • Shanghai Sixth People's Hospital
    • Shanxi
      • Xian, Shanxi, Kina
        • Aktiv, inte rekryterande
        • Xi'an Hong Hui Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina
        • Rekrytering
        • West China Hospital of Sichuan University
        • Kontakt:
          • Yong Zhou, MD
        • Huvudutredare:
          • Yong Zhou, MD
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Rekrytering
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • Kontakt:
          • Zhaoming Ye, MD
        • Huvudutredare:
          • Zhaoming Ye, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

12 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Histologically confirmed solid tumors that have progressed on or intolerant to standard therapy or whom no standard therapy exists
  • ECOG (electrocorticogram) performance status 0~1
  • Life expectancy ≥ 3 months
  • Adequate organ function and bone marrow function

For patients with tenosynovial giant cell tumor (TGCT) :

  1. A diagnosis of TGCT [i ncluding pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT TS) (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist,and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi disciplinary tumor board);
  2. Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2 cm is required), assessed from MRI scans;
  3. Others

For Adolescent Cohort (China only):

  1. Patient and/or legally acceptable representative should understand, sign, and date the written voluntary informed consent form prior to screening.
  2. Adolescents≥ 12 years of age and < 18 years at the time of informed consent.
  3. Body weight ≥ 40kg.
  4. A diagnosis of TGCT [including pigmented villonodular synovitis (PVNS) or giant cell tumors of the tendon sheath (GCT-TS)] (i) that has been histologically confirmed either by local laboratory, and (ii) unresectable, defined as confirmed by assessment by at least two clinical experts (including at least one independent expert who is not part of the trial conduct), meeting one of the following 2 requirements: ①located in a complex anatomical site, is extensively invasive, and cannot be completely resected; ②surgical operation may cause dysfunction or serious complications.
  5. Measurable disease as defined by RECIST v1.1 (with at least 1 lesion ≥ 2 cm is required), assessed by MRI scans in local site prior to dosing.
  6. Others

Exclusion Criteria:

  • Known allergy or hypersensitivity to any component of the investigational drug product Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating factor 1 receptor) pathway inhibitors
  • Known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study treatment
  • Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
  • Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter) prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment)
  • Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence
  • Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with the exception of alopecia and vitiligo
  • Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first dose of study drug
  • Concomitant use of strong inhibitors or inducers of CYP3A4
  • Active central nervous system (CNS) metastases
  • Impaired cardiac function or clinically significant cardiac disease
  • Patients with Gilbert's Syndrome or other underlying conditions that may lead to a greater likelihood of developing LFT(liver function test) abnormalities during the study
  • Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection
  • Refractory/uncontrolled ascites or pleural effusion
  • Pregnant or nursing

For patients with tenosynovial giant cell tumor (TGCT) :

  1. Known allergy or hypersensitivity to any component of the investigational drug product
  2. For expansion part, previous treatment with CSF 1/CSF 1R pathway inhibitors (not applicable for TGCT patients in US)
  3. Others

For Adolescent Cohort (China only):

  1. Known allergy or hypersensitivity to any component of the investigational drug product.
  2. Previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R prior to first dosing. However, patients who have received prior treatment with multi-kinase inhibitors that include the CSF-1/CSF-1R pathway are allowed, such as Imatinib and Nilotinib.
  3. Know additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ.
  4. Others

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ABSK021

Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles.

ABSK021 oral capsule

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence and Severity of AEs
Tidsram: Through study completion, an average of 6 months

Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)

Through study completion, an average of 6 months
Incidence of DLTs
Tidsram: At the end of Cycle 1 (each cycle is 28 days)

DLT(dose-limiting toxicity)

At the end of Cycle 1 (each cycle is 28 days)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PFS
Tidsram: From date of enrollment until the date of first documented progression or death, assessed up to 12 months

Progression-Free Survival (PFS)

From date of enrollment until the date of first documented progression or death, assessed up to 12 months
DoR
Tidsram: From date of enrollment until the date of first documented progression or death, assessed up to 12 months

Duration of Response (DoR)

From date of enrollment until the date of first documented progression or death, assessed up to 12 months
DCR
Tidsram: 24 weeks post-dose

Disease Control Rate (DCR)

24 weeks post-dose
Cmax
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose

The peak plasma concentration of a drug after administration

Pre-dose and multiple timepoints (up to 72 hours) post-dose
tmax
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose

Time to reach Cmax

Pre-dose and multiple timepoints (up to 72 hours) post-dose
Bioavailability
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose

The systemically available fraction of a drug

Pre-dose and multiple timepoints (up to 72 hours) post-dose
Elimination half-life
Tidsram: Pre-dose and multiple timepoints (up to 72 hours) post-dose

The time required for the concentration of the drug to reach half of its original value

Pre-dose and multiple timepoints (up to 72 hours) post-dose

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Siqing Fu, MD, M.D. Anderson Cancer Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 januari 2020

Primärt slutförande (Beräknad)

31 december 2031

Avslutad studie (Beräknad)

31 december 2031

Studieregistreringsdatum

Först inskickad

27 november 2019

Först inskickad som uppfyllde QC-kriterierna

9 december 2019

Första postat (Faktisk)

10 december 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera